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David M. Cutler and Ernst R. Berndt 
Measuring the output of the medical sector has been a long-standing pol- 
icy concern. With the United States and other developed countries spend- 
ing so much on medical care (7 to 14 percent of GDP), health care analysts 
invariably ask what one obtains for all these expenditures. Answering this 
question requires measuring  the output of the medical care sector.  Na- 
tional income accountants face the same problem. National income ac- 
counts divide nominal spending growth into changes in prices and changes 
in quantities. But neither prices nor quantities can be estimated without 
an accurate measure of the medical care industry output. 
At the conceptual level, an appropriate measure of medical care output 
is clear-the  health gains resulting from medical care. If increased medical 
spending leads to health improvements worth more than their cost, then 
medical care productivity is increasing. If spending increases lead to less 
valuable increases in health, medical care productivity is falling. 
The difficulty rests in implementing this framework. Measuring health 
status is difficult, and attributing changes in health status to a particular 
factor such as medical care is even more challenging. Thus, productivity 
estimation for medical care has necessarily been infrequent and tentative. 
Substantial research has recently  been directed  at this issue, however. 
The “outcomes movement” in health economics is an attempt to measure 
the health impact of medical care, Research conducted at and supported 
by public agencies such as the Bureau of Labor Statistics (BLS), the Bu- 
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reau of Economic Analysis (BEA), and the National Institute on Aging, 
as well as by private pharmaceutical firms such as Eli Lilly and Company, 
have investigated the pricing of medical services. In  1996, the National 
Bureau of Economic Research, drawing together many of its own research 
efforts in this field, organized a study team on the Economics of Medical 
Treatments. 
After several years of research, and in consultation with the Bureau of 
Labor Statistics, the Bureau of Economic Analysis, the National Institute 
on Aging, and Eli  Lilly and Company, it was decided  to take stock of 
where we  are. This volume is the result of that assessment. 
The chapters in this volume cover a very wide range, from theoretical 
discussions of  how medical care productivity  ought to be measured, to 
empirical analyses of prices and productivity  for different illnesses and 
medical conditions,  to nonmedical factors that affect health  status and 
mortality. The chapters in this volume make a substantial contribution to 
the measurement  of medical care prices, output, and productivity. To- 
gether, they illustrate where we  are now, what can be done in the near fu- 
ture, and where price index measurement in this vital field can move feas- 
ibly and fruitfully in years to come. 
This volume is organized around four thematic areas, which we  now 
briefly summarize. 
Conceptual Issues in Medical Care Prices and Productivity 
The first topic is the methodology for measuring productivity in medical 
care. Medical care is not the only sector of the economy where productiv- 
ity measurement is difficult, of  course. Productivity measurement is dif- 
ficult in many of the service sectors. The first section of the volume com- 
pares and contrasts the theoretical issues in productivity measurement in 
medical care with those in other sectors. 
In his chapter “What’s Different about Health? Human Repair and Car 
Repair in National Accounts and in National Health Accounts,” Jack E. 
Triplett argues that health care is not in fact wholly different from other 
services, such as car repair. Both markets, for example, have characteristics 
of asymmetric information and moral hazard. 
Triplett takes as a starting point in the human repair framework that 
the focal point of expenditures is that for treating diseases and conditions, 
and not, for example, expenditures for hospitals. This implies that national 
health  accounts must  be  organized  and integrated  into  cost-of-disease 
accounts.  Moreover, instead  of  looking just  at market transactions, for 
human repair one must consider what medical resources actually do for 
health. This means assessing the “production function” for health status 
outcomes.  The integration  of  economic  and outcomes research  distin- 
guishes, at least in degree, human repair from car repair accounting. Introduction  3 
In his chapter “Theoretical Foundations of Medical Cost-Effectiveness 
Analysis: Implications for the Measurement of Benefits and Costs of Med- 
ical  Interventions,” David  Meltzer  explores the theoretical foundations 
underlying measures of medical care outcomes. The difficulty in measur- 
ing the costs and benefits of medical treatments is one of the most salient 
differences between medical care and other industries. Meltzer notes two 
key dimensions along which the literature has had substantial debate: how 
to measure the quality of life for individuals with particular health states, 
and how cost-effectiveness  analysis should deal with costs occurring in the 
future, after the initial medical treatment has been provided. 
On the first point, Meltzer argues that ideally quality of life should be 
measured with revealed preference analysis-using  the choices that indi- 
viduals actually make between different treatment options to infer their 
value of different health states. An example is treatment for diabetes. In 
comparing therapies with different levels of intensity and long-run quality 
of life gains, Meltzer argues that the choices that diabetic patients make 
are a reasonable guide to the underlying utility they receive. He shows how 
this insight can be turned  into an estimate  of  quality  of life useful for 
outcome valuation purposes. 
On the second point, Meltzer argues that productivity measurement in 
medical care must consider the future costs resulting from medical treat- 
ments provided today. If medical intervention lengthens an individual’s life 
by ten years, for example, Meltzer shows that the costs of sustaining that 
person for the ten additional years must be attributed to the intervention, 
just as the benefits of the ten years of additional life are. Meltzer shows 
that treating future costs and benefits consistently can have a large effect 
on our perception of the relative ranking of different interventions. 
Another way in which health care differs from many (but not all) other 
service industries is that most production takes place in nonprofit organi- 
zations. Yet  relatively little is known about the economic forces affecting 
productivity in this industry. In their chapter “Medical Care Output and 
Productivity in the Nonprofit Sector,” Tomas Philipson and Darius Lakda- 
walla specify medical service provider objective functions that allow for 
productivity differences between for-profit and nonprofit producers to be 
interpreted as evidence for differences in preferences, rather than in costs. 
Their model predicts that when both coexist, nonprofits are larger and less 
efficient in input use (“input preferrers”), but nevertheless become more 
numerous than for-profit firms, even though the nonprofits exhibit higher 
average and marginal costs. The nonprofits thrive because of their depen- 
dence on donations and tax advantages. The authors interpret empirical 
evidence from the nursing home industry as supportive of their frame- 
work, although discussant Richard G. Frank interprets this evidence as 
being more ambiguous. 
This thematic section on conceptual issues ends with a chapter by Ernst 4  David M. Cutler and Ernst R. Berndt 
Berndt, David Cutler, Richard Frank, the late Zvi Griliches, Joseph New- 
house,  and Jack  Triplett, “Price Indexes for Medical  Care Goods and 
Services: An Overview of Measurement Issues,” summarizing the NBER 
methodology to price and productivity measurement. The Berndt et al. 
chapter has two goals. First, it discusses the conceptual and measurement 
issues that  underlie  construction  of  medical  care price  indexes in  the 
United  States,  particularly  the  medical  care  consumer  price  indexes 
(MCPIs) and medical-related producer price indexes (MPPIs). The prob- 
lems in price measurement are multiple: Insurance makes the cost of medi- 
cal care to consumers lower than its cost to society; physicians may not 
do exactly what well-informed patients would want; technological progress 
makes the basket of goods different over time; and organizational changes 
such as managed care change the basis of pricing in the market. Because 
of these various factors, market outcomes are not likely to be efficient, and 
therefore market transactions data cannot be relied upon to reveal mar- 
ginal valuations. This implies that productivity measurement must go be- 
yond the method of hedonic analysis that is now standard in other markets 
or industries. 
The second part of the Berndt et al. chapter describes procedures cur- 
rently used by the BLS in constructing MCPIs and MPPIs, including re- 
cent revisions, and then considers alternative notions of medical care out- 
put. Whereas historical BLS methods relied on pricing all of the detailed 
services that a patient used, the authors argue instead that the focus should 
be on more aggregated pricing of an episode of treatment. The authors 
outline features of  a proposed new experimental price index-a  medical 
care expenditure price  index-that  is more suitable for evaluation  and 
analyses of  medical care cost changes than are the current  MCPIs and 
MPPIs. They propose that, in addition to the MCPIs and MPPIs, some 
federal statistical agency publish an experimental medical care expendi- 
ture price index. 
Current State of Measurement 
In the second section of the volume, the current state of official govern- 
ment measurement regarding price and productivity measurement in med- 
ical care is summarized and reviewed. The first two chapters discuss the 
current BLS methodology for the consumer and producer price indexes in 
medical care, respectively. 
In “Medical Care in the Consumer Price Index,” Ina Kay Ford  and 
Daniel H. Ginsburg provide details and discuss implications of changes 
introduced into the January  1998 major revision of the Consumer Price 
Index (CPI). Item weights are of course changed in this revision. Because 
the scope of the CPI is limited to consumers’ direct out-of-pocket  pay- 
ments plus the employee-paid share of employer-provided health insur- Introduction  5 
ance, the expenditure share of  medical care in  the CPI (7.4  percent  in 
1995) is much less than its share in the personal consumption expenditure 
component of GDP (17.9 percent). The Laspeyres fixed quantity basis of 
the CPI also resulted in the 1997 relative importance weight for medical 
care of about 7.5 percent being considerably larger than the new weight of 
5.6 percent embodied in the 1998 revision. 
Other CPI revisions introduced in 1998 include rotating the sample of 
categories of commodities rather than subsets of the pricing areas, which 
permits more frequent updating of  selected item strata. To  capture pos- 
sible inpatient-outpatient substitution, the new hospital CPI incorporates 
hospital room expenses, charges for other inpatient services, and the cost 
of outpatient services all under one umbrella, rather than as distinct item 
strata. The authors note continuing conceptual and implementation chal- 
lenges in  pricing medical insurance, and conclude with  a discussion of 
input versus outcomes approaches to the choice of what it is that is being 
priced by  the medical CPI. 
For quite some time now, the BLS has expanded the scope of its pro- 
ducer price indexes (PPIs) to include service sector industries, not just 
goods producing sectors. In their chapter, “Health Care Output and Prices 
in the Producer Price Index,” BLS economists Dennis Fixler and Mitchell 
Ginsburg provide a very detailed and thorough description of how PPIs 
are now being constructed for the main industries composing the health 
care sector of the economy. By linking price quotes to patient diagnoses 
and procedural codes, these health care PPIs now attempt to price much 
more closely episodes of typical treatments, rather than just pricing dis- 
crete medical inputs such as hospital days. These developments in the PPI 
are very significant. A major continuing difficulty, however, is that the PPI 
program has as its organizing structure the Standard Industrial Classifica- 
tion (SIC) system, and many medical procedures combine outputs from 
several SIC industries. For example, the treatment  of  outpatient mental 
health combines inputs from psychiatrists and pharmaceuticals, the latter 
being classified within the SIC manufacturing sector. 
The third paper in this section examines one of the long-standing issues 
in medical care measurement-the  differences between different federal 
health care accounts in the United States. Both the Health Care Financing 
Administration and the Bureau of Economic Analysis produce and pub- 
lish a set of national health accounts, where they track medical spending 
in the economy as a whole. But the two accounts differ by  a considerable 
amount-3  to 4 percent in 1996, for example. With multiple measures of 
medical care spending, it has been difficult for users to obtain an accurate 
handle on the scope of  the medical sector. Arthur  Sensenig and Ernest 
Wilcox report on an attempted reconciliation between these two accounts 
in their chapter “National Health AccountslNational Income and Product 
Accounts Reconciliation.” Sensenig and Wilcox highlight both conceptual 6  David M. Cutler and Ernst R. Berndt 
and data differences between the two accounts. Conceptually, the two ac- 
counts differ in their use of revenues versus expenditures. The data used 
also differ, depending on whether they are benchmarked to other industry 
surveys. In a changing industry such as medical care, where revenues and 
costs may differ considerably  (as they do, for example, in not-for-profit 
hospitals), these differences can be quite significant. Tracking these differ- 
ences might therefore have a substantial impact on output and productiv- 
ity estimates in the industry. 
Recent Developments 
The third section of this volume presents  new  empirical  analyses of 
price, output, and productivity measurement in medical care. The authors 
of these papers generally focus on treatment  of a particular  condition, 
such as heart attacks or acute phase depression. The reason for this narrow 
focus was detailed in the earlier conceptual section of the volume: Because 
productivity analysis requires direct measurement of health outcomes, it 
needs to be done at the level of a specific disease or illness. 
In  their  chapter  “Pricing  Heart Attack  Treatments,”  David  Cutler, 
Mark McClellan, Joseph Newhouse, and Dahlia Remler estimate price 
indexes for heart attack treatments, demonstrating the techniques that are 
currently used in official price indexes and presenting several alternatives. 
Cutler et al. consider two types of prices indexes: a service price index, 
which  prices  specific treatments  provided,  and a  cost-of-living index, 
which prices the health outcomes of patients. Both indexes are compli- 
cated by  price measurement issues. For example, list prices and transac- 
tions prices are fundamentally different in the medical care marketplace. 
The development of new or modified medical treatments further compli- 
cates the comparison of “like” goods over time. Furthermore, the cost-of- 
living index is hampered by  the need to determine how much of  health 
improvement results from medical treatments in comparison to other fac- 
tors, such as lifestyle changes. 
Cutler et al. describe methods to address each of these obstacles. They 
employ national data on treatments and outcomes for Medicare benefi- 
ciaries who have had a heart attack to measure the cost of living for med- 
ical care. Cutler et al. conclude that, while traditional price indexes when 
applied to heart attack treatments are rising at roughly 3 percent per year 
above general inflation, a corrected service price index is rising at perhaps 
1 to 2 percent per year above general inflation, and the cost-of-living index 
is falling by  1 to 2 percent per year relative to general inflation. 
An alternative method for measuring the impact of medical care in- 
volves use of clinical trial evidence on medical treatments. Meta-analyses 
based on clinical trials can be used to infer the impact of medical treat- 
ments on outcomes. The more medically oriented chapter by Paul Heiden- Introduction  7 
reich and Mark McClellan, “Trends in Heart Attack Treatment and Out- 
comes,  1975-1 995,”  demonstrates  this  methodology.  Heidenreich  and 
McClellan summarize the voluminous medical literature on the efficacy of 
treatment  for myocardial  infarction  (heart attacks). They conclude that 
over the 1975-1995  period, medical treatments played a large role in im- 
proving heart attack survival rates. Specifically, they conclude that about 
two thirds of increased survival resulted from medical advances, most no- 
tably the diffusion of pharmaceutical therapies such as aspirin, beta block- 
ers, and thrombolytics. Invasive technologies such as primary angioplasty 
also  contributed  significantly  to  increased  survival.  Heidenreich  and 
McClellan’s analysis thus complements the findings of Cutler et al. on the 
efficacy of medical treatments for myocardial infarction. 
The next chapter, “Measuring the Value of Cataract Surgery,” provides 
a dramatic example of  the impact of changing medical technologies on 
reducing the burden of an ophthalmic condition, namely  cataracts. The 
authors, Irving Shapiro, Matthew D. Shapiro, and David W. Wilcox begin 
by documenting changes in the last half-century for surgically extracting 
cataracts. Incisions and suturing have improved, intraocular lens implants 
have eliminated the need for cataract eyeglasses or contact lenses, and sur- 
gery is now done largely on an outpatient basis, resulting in greatly im- 
proved  quality of outcomes. Patients have much faster ambulation, face 
lower rates of complications,  and have  better  postoperative  visual  out- 
comes. Because of these cost reductions  and quality improvements, pa- 
tients with less severe disease are now increasingly having cataract surgery, 
earlier in the course of the disease, with more long-lived benefits. While 
precise measurement is still challenging, it is clear that although monetary 
costs have been relatively flat over time, in any reasonable quality-adjusted 
world the real price of cataract extraction  has fallen sharply with  time. 
The authors conclude with a discussion about the generalizability of their 
findings, and urge that future research focus on taking into account how 
the population  of patients receiving treatment  changes endogenously in 
response to changes in cost. 
In their chapter “Hedonic Analysis of Arthritis Drugs,” Iain Cockburn 
and Aslam Anis focus on measuring  price  indexes for pharmaceuticals 
used  in the treatment  of rheumatoid  arthritis. Although this is a wide- 
spread and debilitating disease with very substantial impacts on the health 
of patients and on the economy, currently the available drugs have limited 
efficacy and serious side effects. Clinical research conducted since these 
products were approved has resulted in substantial revisions to the body 
of  scientific information  available to physicians.  The relative  quality of 
these drugs (as represented by efficacy and toxicity measurements reported 
in peer-reviewed clinical trials) has changed markedly over the past fifteen 
years. Cockburn and Anis examine how prices relate to quality. Somewhat 
surprisingly, they find that in this therapeutic class, prices are only weakly 8  David M. Cutler and Ernst R. Berndt 
related to quality. They do, however, find a relationship between changes 
in  reported  efficacy and toxicity, and  the  evolution of  quantity  shares 
within this therapeutic class. Thus the Cockburn-Anis research reminds 
us that generalization across diverse medical conditions is hazardous, and 
that disease-by-disease analysis is instead necessary. 
The chapter by Ernst Berndt, Susan Busch, and Richard Frank, “Treat- 
ment Price Indexes for Acute Phase Major Depression,” focuses on alter- 
native price indexes for acute phase unipolar (major) depression. Making 
use of results from the published clinical literature and from official federal 
government treatment guideline standards, Berndt et al. begin by identi- 
fying therapeutically similar treatment bundles. These bundles can then 
be linked and weighted to construct price indexes for specific forms of 
major depression. In doing so, Berndt et al. construct CPI- and PPI-like 
medical price indexes that deal with prices of treatment episodes rather 
than prices of discrete inputs, that are based on transaction rather than 
list prices, that take quality changes and expected outcomes into account, 
and that employ current, time-varying expenditure weights in the aggrega- 
tion computations. Berndt et al. find that, regardless of which index num- 
ber procedure is employed, the treatment price index for the acute phase 
of  major  depression  has  hardly  changed, remaining  at  1.00 or  falling 
slightly to around 0.97. This index grows considerably less rapidly than 
the various official PPIs. Thus, relative to overall inflation, the price index 
for the treatment of the acute phase of major depression has fallen over 
the period 1991-95. 
Berndt et al. further find that a hedonic approach to price index mea- 
surement yields broadly similar results. These results imply that given a 
budget for treatment of depression, more could be accomplished in 1995 
in terms of outcomes than in 1991. The results suggest that at least in the 
case of acute phase major depression,  aggregate spending increases are 
due primarily to a larger number of effective treatments being provided, 
rather than being the result of price increases. 
Extensions of the Frontier 
The final section of the volume tackles more exploratory issues in output 
measurement-previously  unstudied issues or extensions to other method- 
ologies. Sherry Glied focuses on nonmedical  sources of  health improve- 
ments for children and adolescents. In her chapter, “The Value of Reduc- 
tions in Child  Injury Mortality  in the United  States,” Glied notes that 
childhood  mortality  rates  have  declined  steadily  over  time  and  across 
causes of death. She investigates alternative explanations for this decline. 
Glied focuses on several potential factors in improved health: changes in 
children’s living circumstances, changes in the professional child injury 
knowledge  base,  changes  in  the information  imparted  to parents,  and Introduction  9 
changes in the regulations surrounding childhood behavior. Using data 
from the National Mortality Detail Files on the number of child deaths by 
age, cause, and state, combined with information from the Current Popula- 
tion Survey on the characteristics of children and their families by state, 
Glied  finds that changes in  children’s living circumstances can explain 
little, if any, of the change in child health. There is limited evidence that 
regulatory interventions intended to change behavior have been important. 
Most  important  is evidence suggesting that changes in the knowledge 
available to parents about child health have become increasingly impor- 
tant. Over time, parents’ time has become less important in producing 
health. These results provide a first effort in understanding the dramatic 
reduction in child injury mortality and also illustrate how the development 
of  scientific information, a public  good, is translated  into private  out- 
comes. However, this scientific information can generate growing inequal- 
ity in those outcomes. 
In their chapter, “Patient Welfare and Patient Compliance: An Empiri- 
cal Framework for Measuring the Benefits from Pharmaceutical Innova- 
tion,” Paul Ellickson, Scott Stern, and Manuel Trajtenberg develop an em- 
pirical framework for evaluating the patient welfare benefits arising from 
pharmaceutical innovations. Ellickson et al. extend previous studies of the 
welfare benefits from innovation, unpacking the separate choices made by 
physicians and patients in pharmaceutical decision making. They develop 
an estimable econometric model which  reflects these choices. The pro- 
posed estimator for patient welfare depends on whether patients comply 
with the prescriptions they receive from physicians, and the motives of 
physicians in their prescription behavior. By  focusing on compliance be- 
havior, the proposed welfare measure reflects a specific economic choice 
made by patients, and thereby addresses to some extent the principal-agent 
relationship that confounds analysis of medical care. 
Ellickson et al. review evidence that the rate of noncompliance ranges 
up to 70 percent, suggesting an important gulf between physician prescrip- 
tion behavior and realized patient welfare. Because physicians act as im- 
perfect but interested agents for their patients, the welfare analysis based 
on compliance must account for the nonrandom selection of patients into 
drugs by their physicians. The paper integrates the choices made by both 
physicians and patients into a unified theoretical framework and suggests 
how  the  parameters  of  such  a  model  could  be  estimated from  health 
claims data. 
The final chapter is by  Frank Lichtenberg, entitled “The Allocation of 
Publicly Funded  Biomedical Research.” Lichtenberg  develops a  simple 
theoretical model of the allocation of public biomedical research expendi- 
ture and presents selected empirical evidence about the determinants of 
this allocation. Lichtenberg notes that the composition of expenditures 
should  depend  on the relative costs as well  as the relative benefits of 10  David M. Cutler and Ernst R. Berndt 
different kinds  of  research. Analysts of technical  change typically have 
data on neither of these, but Lichtenberg argues that the burden of illness 
is indicative of the potential benefit of achieving advances against different 
diseases, allowing him to infer how closely disease costs and benefits are 
aligned. 
In  his  empirical  work,  Lichtenberg  calculates  distributions  of 
government-funded  biomedical  research  expenditure,  by  disease,  from 
records of  all research projects supported by the US. Public Health Ser- 
vice. To  obtain a reasonably complete accounting of disease burden, he 
utilizes data on both the dying (from the Vital Statistics-Mortality  Detail 
file) and the living (from the National Health Interview Survey). Lichtenb- 
erg finds a very strong positive relationship across diseases between total 
life years lost before age sixty-five and public R&D expenditures. He also 
finds that the amount of publicly funded research on a disease decreases 
with the share of life years before age sixty-five lost to the diseases by 
nonwhites. This could reflect the fact that lack of scientific knowledge is a 
less important cause of premature mortality among nonwhites than it is 
among whites. The number of research grants mentioning a chronic condi- 
tion is uncorrelated with the number of people with the condition, but is 
very strongly positively related to the number of people whose activities 
are limited by that condition. Finally, Lichtenberg finds that there tends to 
be  more  research  about  chronic  conditions  that  are  prevalent  among 
people living in low-income households, and that are prevalent among the 
youngest (under age eighteen) and the oldest (above age seventy-five). 
Concluding Observations 
Although the chapters in this volume are diverse, two themes predomi- 
nate-one  expected, and the other a surprise to many. First, accounting 
for changes in medical outcomes is difficult but essential-particularly  as 
outcomes improvements increasingly involve the quality rather than the 
length or quantity  of life. While current measurement methods are not 
entirely satisfactory, progress is being made and additional enhancements 
to measuring medical care productivity are very likely in the near future. 
Second, the conventional wisdom that technological advances in medicine 
are a driving force of increasing health care costs is much too simplistic 
and deserves much more careful empirical scrutiny. 
Some technological developments, such as those involving treatment for 
cataracts and for acute phase depression, enable a larger proportion of the 
affected population to tolerate and benefit from treatment.  In turn, the 
greater treatment effectiveness creates incentives for more intensive and 
more frequent diagnoses. While the number of patients receiving effective 
treatment may increase as a result of the technological developments, and 
total treatment  expenditures may increase, in many cases the treatment Introduction  11 
cost per patient episode has fallen. Treatment quantity rather than treat- 
ment price may well be the largest driver of expenditure escalation. 
Finally, the chapters in this volume were written several years ago, and 
one might ask, why publish them now? There are several compelling rea- 
sons. First, the issues addressed in this volume-the  reliable measurement 
of medical care sector output and productivity-continue  to persist and 
frustrate private and public sector analysts, in the United States and else- 
where. As the population age structure becomes older in the coming de- 
cades in much  of  the world, benefits from being able to measure more 
reliably the efficiency and productivity of a growing medical care sector 
will be increasingly valuable. In brief, issues involving medical care output 
measurement are persistent and increasingly important. Second, the litera- 
ture on measuring medical care output and productivity is still unsettled 
and in flux, and it is important to understand the diverse and wide-ranging 
natures of the alternative approaches. This allows us to take stock of where 
we  are. It also allows statistical agencies to evaluate changes in price and 
productivity measurement for medical care. Third, to facilitate future re- 
search, it is particularly valuable and useful to assemble and put into one 
volume a  diverse  collection  of  conceptual  and empirical  analyses,  au- 
thored  by  leading researchers. That goal, we  believe, is  achieved in this 
volume. This Page Intentionally Left Blank